The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications

被引:22
作者
Marques, Pedro [1 ]
Silva, Ana Luisa [1 ,2 ]
Lopez-Presa, Dolores [3 ]
Faria, Claudia [4 ]
Bugalho, Maria Joao [1 ,2 ]
机构
[1] Hosp Santa Maria, Ctr Hosp Univ Lisboa Norte CHULN, Dept Endocrinol, Lisbon, Portugal
[2] Univ Lisbon, Fac Med, Lisbon, Portugal
[3] Hosp Santa Maria, Ctr Hosp Univ Lisboa Norte CHULN, Dept Pathol, Lisbon, Portugal
[4] Hosp Santa Maria, Neurosurg Dept, Ctr Hosp Univ Lisboa Norte CHULN, Lisbon, Portugal
关键词
Pituitary adenoma; Tumor microenvironment; Inflammation; Immune cell; Cytokine; Immunotherapy; ENDOTHELIAL GROWTH-FACTOR; ARYL-HYDROCARBON RECEPTOR; FOLLICULO-STELLATE CELLS; TUMOR-ASSOCIATED MACROPHAGES; LEUKEMIA INHIBITORY FACTOR; CANCER-ASSOCIATED FIBROBLASTS; NORMAL ANTERIOR-PITUITARY; COLLAGEN-PRODUCING CELLS; HORMONE RELEASE; GENE-EXPRESSION;
D O I
10.1007/s11102-022-01211-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The microenvironment of pituitary adenomas (PAs) includes a range of non-tumoral cells, such as immune and stromal cells, as well as cell signaling molecules such as cytokines, chemokines and growth factors, which surround pituitary tumor cells and may modulate tumor initiation, progression, invasion, angiogenesis and other tumorigenic processes. The microenvironment of PAs has been actively investigated over the last years, with several immune and stromal cell populations, as well as different cytokines, chemokines and growth factors being recently characterized in PAs. Moreover, key microenvironment-related genes as well as immune-related molecules and pathways have been investigated, with immune check point regulators emerging as promising targets for immunotherapy. Understanding the microenvironment of PAs will contribute to a deeper knowledge of the complex biology of PAs, as well as will provide developments in terms of diagnosis, clinical management and ultimately treatment of patients with aggressive and/or refractory PAs.
引用
收藏
页码:363 / 382
页数:20
相关论文
共 208 条
[1]   Epidemiology and etiopathogenesis of pituitary adenomas [J].
Aflorei, Elena D. ;
Korbonits, Marta .
JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (03) :379-394
[2]   HUMAN AND MURINE PITUITARY EXPRESSION OF LEUKEMIA INHIBITORY FACTOR - NOVEL INTRAPITUITARY REGULATION OF ADRENOCORTICOTROPIN HORMONE SYNTHESIS AND SECRETION [J].
AKITA, S ;
WEBSTER, J ;
REN, SG ;
TAKINO, H ;
SAID, J ;
ZAND, O ;
MELMED, S .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :1288-1298
[3]   Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function - A model for human pituitary Rathke's cysts [J].
Akita, S ;
Readhead, C ;
Stefaneanu, L ;
Fine, J ;
TampanaruSarmesiu, A ;
Kovacs, K ;
Melmed, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) :2462-2469
[4]   History and perspectives of pituitary folliculo-stellate cell research [J].
Allaerts, W ;
Vankelecom, H .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (01) :1-12
[5]  
Andoh A, 2002, INT J MOL MED, V10, P89
[6]  
Arita Kazunori, 2004, Hiroshima Journal of Medical Sciences, V53, P23
[7]   INTERLEUKIN-2 AND INTERLEUKIN-2 RECEPTOR EXPRESSION IN HUMAN CORTICOTROPIC ADENOMA AND MURINE PITUITARY CELL-CULTURES [J].
ARZT, E ;
STELZER, G ;
RENNER, U ;
LANGE, M ;
MULLER, OA ;
STALLA, GK .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) :1944-1951
[8]   Pathophysiological role of the cytokine network in the anterior pituitary gland [J].
Arzt, E ;
Pereda, MP ;
Castro, CP ;
Pagotto, U ;
Renner, U ;
Stalla, GK .
FRONTIERS IN NEUROENDOCRINOLOGY, 1999, 20 (01) :71-95
[9]   INTERLEUKIN INVOLVEMENT IN ANTERIOR-PITUITARY CELL-GROWTH REGULATION - EFFECTS OF IL-2 AND IL-6 [J].
ARZT, E ;
BURIC, R ;
STELZER, G ;
STALLA, J ;
SAUER, J ;
RENNER, U ;
STALLA, GK .
ENDOCRINOLOGY, 1993, 132 (01) :459-467
[10]   CHARACTERIZATION OF INTERLEUKIN-2 (IL-2) RECEPTOR EXPRESSION AND ACTION OF IL-2 AND IL-6 ON NORMAL ANTERIOR-PITUITARY CELL-GROWTH [J].
ARZT, E ;
SAUER, J ;
BURIC, R ;
STALLA, J ;
RENNER, U ;
STALLA, GK .
ENDOCRINE, 1995, 3 (02) :113-119